文献速递泌尿男性生殖肿瘤

奥拉帕利与医生选择的下一代激素药物在携带同源重组修复基因改变的转移性去势抵抗性前列腺癌患者中的疼痛与健康相关生活质量比较(PROfound):一项开放标签、随机、3期试验

Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial.
PubMed 文献 · Lancet Oncol · 2022-02-11

PROfound研究显示,在携带同源重组修复基因改变且既往下一代激素药物治疗后进展的转移性去势抵抗性前列腺癌患者中,奥拉帕利较对照药物显著延长影像学无进展生存期和总生存期。本文评估队列A患者的疼痛和患者为中心的健康相关生活质量指标,奥拉帕利在至疼痛进展时间、疼痛干扰评分、至首次阿片类药物使用时间、FACT-P总评分临床意义改善比例和至首次症状性骨骼相关事件时间方面均优于对照。

要点

  • 队列A中奥拉帕利组至疼痛进展时间显著长于对照组(HR 0.44)。
  • 奥拉帕利组疼痛干扰评分总体调整后均值变化优于对照组(差值-0.85)。
  • 奥拉帕利组FACT-P总评分临床意义改善比例高于对照组(比值比8.32)。

核心结论

  • 在携带同源重组修复基因改变且既往下一代激素药物治疗后进展的转移性去势抵抗性前列腺癌患者中,奥拉帕利与两种对照药物相比与疼痛负担减轻和健康相关生活质量更好保持相关。
  • 研究结果支持PROfound研究中观察到的影像学无进展生存期和总生存期改善的临床获益。

研究设计与样本

  • 开放标签、随机、3期研究,患者按2:1随机分配接受奥拉帕利片(300 mg口服每日两次)或对照药物(恩扎卢胺片160 mg口服每日一次,或阿比拉酮片1000 mg口服每日一次加泼尼松片5 mg口服每日两次)。
  • 纳入年龄≥18岁、携带15个基因中一个基因改变(队列A:BRCA1、BRCA2或ATM;队列B:BRIP1、BARD1、CDK12、CHEK1、CHEK2、FANCL、PALB2、PPP2R2A、RAD51B、RAD51C、RAD51D和RAD54L)且既往下一代激素药物治疗后疾病进展的转移性去势抵抗性前列腺癌患者。
  • 按既往紫杉烷使用和可测量疾病分层。
  • 本文报告队列A的预设次要终点:疼痛、健康相关生活质量、症状性骨骼相关事件和至首次因癌症相关疼痛使用阿片类药物的时间。
  • 疼痛采用简明疼痛量表-简表评估,健康相关生活质量采用癌症治疗功能评估-前列腺量表(FACT-P)评估。

主要发现

  • 2017年2月6日至2019年6月4日期间,队列A共入组245例患者接受研究治疗(奥拉帕利组162例[66%],对照组83例[34%])。
  • 数据截止时所有患者的中位随访时间:奥拉帕利组6.2个月(IQR 2.2-10.4),对照组3.5个月(IQR 1.7-4.9)。
  • 队列A中,奥拉帕利组至疼痛进展中位时间显著长于对照组(奥拉帕利组中位未达到[95% CI未达到-未达到] vs 对照组9.92个月[5.39-未达到];HR 0.44[95% CI 0.22-0.91];p=0.019)。
  • 奥拉帕利组疼痛干扰评分也更好(总体调整后均值较基线变化差值-0.85[95% CI -1.31至-0.39];pnominal=0.0004)。
  • 至疼痛严重程度进展中位时间两组均未达到(两组95% CI均未达到-未达到;HR 0.56[95% CI 0.25-1.34];pnominal=0.17)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The PROfound study showed significantly improved radiographical progression-free survival and overall survival in men with metastatic castration-resistant prostate cancer with alterations in homologous recombination repair genes and disease progression on a previous next-generation hormonal drug who received olaparib then those who received control. We aimed to assess pain and patient-centric health-related quality of life (HRQOL) measures in patients in the trial. METHODS: In this open-label, randomised, phase 3 study, patients (aged ≥18 years) with metastatic castration-resistant prostate cancer and gene alterations to one of 15 genes (BRCA1, BRCA2, or ATM [cohort A] and BRIP1, BARD1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, and RAD54L [cohort B]) and disease progression after a previous next-generation hormonal drug were randomly assigned (2:1) to receive olaparib tablets (300 mg orally twice daily) or a control drug (enzalutamide tablets [160 mg orally once daily] or abiraterone tablets [1000 mg orally once daily] plus prednisone tablets [5 mg orally twice daily]), stratified by previous taxane use and measurable disease. The primary endpoint (radiographical progression-free survival in cohort A) has been previously reported. The prespecified secondary endpoints reported here are on pain, HRQOL, symptomatic skeletal-related events, and time to first opiate use for cancer-related pain in cohort A. Pain was assessed with the Brief Pain Inventory-Short Form, and HRQOL was assessed with the Functional Assessment of Cancer Therapy-Prostate (FACT-P). All endpoints were analysed in patients in cohort A by modified intention-to-treat. The study is registered with ClinicalTrials.gov, NCT02987543. FINDINGS: Between Feb 6, 2017, and June 4, 2019, 245 patients were enrolled in cohort A and received study treatment (162 [66%] in the olaparib group and 83 [34%] in the control group). Median duration of follow-up at data cutoff in all patients was 6·2 months (IQR 2·2-10·4) for the olaparib group and 3·5 months (1·7-4·9) for the control group. In cohort A, median time to pain progression was significantly longer with olaparib than with control (median not reached [95% CI not reached-not reached] with olaparib vs 9·92 months [5·39-not reached] with control; HR 0·44 [95% CI 0·22-0·91]; p=0·019). Pain interference scores were also better in the olaparib group (difference in overall adjusted mean change from baseline score -0·85 [95% CI -1·31 to -0·39]; pnominal=0·0004). Median time to progression of pain severity was not reached in either group (95% CI not reached-not reached for both groups; HR 0·56 [95% CI 0·25-1·34]; pnominal=0·17). In patients who had not used opiates at baseline (113 in the olaparib group, 58 in the control group), median time to first opiate use for cancer-related pain was 18·0 months (95% CI 12·8-not reached) in the olaparib group versus 7·5 months (3·2-not reached) in the control group (HR 0·61; 95% CI 0·38-0·99; pnominal=0·044). The proportion of patients with clinically meaningful improvement in FACT-P total score during treatment was higher for the olaparib group than the control group: 15 (10%) of 152 evaluable patients had a response in the olaparib group compared with one (1%) of evaluable 77 patients in the control group (odds ratio 8·32 [95% CI 1·64-151·84]; pnominal=0·0065). Median time to first symptomatic skeletal-related event was not reached for either treatment group (olaparib group 95% CI not reached-not reached; control group 7·8-not reached; HR 0·37 [95% CI 0·20-0·70]; pnominal=0·0013). INTERPRETATION: Olaparib was associated with reduced pain burden and better-preserved HRQOL compared with the two control drugs in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations who had disease progression after a previous next-generation hormonal drug. Our findings support the clinical benefit of improved radiographical progression-free survival and overall survival identified in PROfound. FUNDING: AstraZeneca and Merck Sharp & Dohme.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Thiery-Vuillemin A, de Bono J, Hussain M, et al. Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial. Lancet Oncol. 2022. PMID: 35157830. doi:10.1016/S1470-2045(22)00017-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。